Check out your Company Bowl for anonymous work chats.
We had an incredible week at HLTH USA boldly showcasing our solutions and how we’re turning health data into precision health action. Some highlights: 💫 In partnership with wastewater epidemiologists and treatment facilities, we monitored the wastewater at HLTH and the surrounding Las Vegas area for 8 different pathogens. 💫 Verily leaders spoke about advancing health equity. Understanding a patient’s context - their race, conditions, and socioeconomic background - allows us to treat them as an individual. We shared a new AI-based reinforcement learning approach that can be applied to drive more equitable health outcomes. 💫 We previewed Verily Lightpath,* a chronic care platform that will turn health data into personalized, proactive care to help people with diabetes, obesity and other metabolic conditions live healthier lives. *To be available in 2026
Sarah Thompson, Verily Head of Clinical Operations, Program and Strategy, spoke on a panel at HLTH USA about implementing scalable plans to maximize investment in the digital era of health and shared the following insights: ▶ "In evaluating digital health solutions, it's important to look for improvement of outcomes over time, and to look across a variety of factors, including improved use of medications and reduction in hospital stays." ▶ "As we plan to integrate AI, we need to ensure there is smooth coordination between the member and their care team. We've created a Co-design Council to get feedback from patients on how they want to engage with AI through their care journey."
From insight to action – in our spotlight session at HLTH USA, David Burdick, Verily Head of Product, Care Solutions, shared an AI-based reinforcement learning approach to dynamically allocate resources. Called a restless multi-armed bandit (RMAB) model, Spotify and Netflix use it for random probability scheduling. When applied to healthcare delivery, there is potential for inadvertent inequities across demographic groups. David talked about a new solution from Verily researchers, equitable RMAB (ERMAB), that can be applied to drive more equitable population health outcomes.
Verily monitors the spread of pathogens to help communities prepare for — and prevent — the spread of infectious diseases. We are currently conducting research to measure the concentration of pathogens in wastewater at HLTH USA and the surrounding Las Vegas area. Check out the latest data and sign up to receive our report highlighting the presence and concentration of pathogens following the event.
We’re turning water into wisdom at HLTH USA. Right now, Verily is monitoring pathogens in the community wastewater in the surrounding Las Vegas area to help inform public health response to infectious disease.
Nothing is more important than protecting a patient’s health data, which is why healthcare companies must have a robust data infrastructure designed for security protection. At Verily, privacy and security are embedded into the design, development and maintenance of our products and infrastructure. 🔒 We’ve implemented numerous layers of controls around the data of our users, customers, and partners, such as strong encryption and tightly restricted and closely monitored role-based access. 🔒 We also empower users to control access to their data according to their own preferences.
Navigating the digital era of health is challenging, but there are opportunities to implement a scalable plan while balancing innovation and impact. Listen in as Verily’s Sarah Thompson, Rasu Shrestha MD MBA, and Mona Siddiqui explore best practices during the HLTH USA Partner Program, hosted by Digital Medicine Society (DiMe), on Sunday, October 20 at 11:00 am.
Through timely community-level detection and quantification, Verily Sightline Wastewater monitoring quickly detects emerging diseases, including the H5 subtype of influenza, and Mpox
As digital biomarkers and measures are increasingly used in cardiovascular research and care, it is essential that we better understand potential sources of bias or inaccurate measurement. In collaboration with co-authors from University of Michigan Medical School, Verily researchers conducted a review of how skin tone may impact the accuracy of photoplethysmography (PPG), which is used in pulse oximetry devices and wearables to assess blood oxygenation (SpO2) and pulse rate (PR). The results show significant discrepancies in the accuracy of FDA-cleared pulse oximeters and commercially available wearable devices across skin tone. The authors share 5 recommendations to improve analytical validation of these devices. Verily is committed to representing all skin tones in our research through the work we’re doing with our digital biomarkers program and Health Equity Center of Excellence (https://veri.ly/3BOBIV7). We can then use these learnings to prevent any bias during our algorithm development, so that our digital measures generalize to all segments of the population.
Today on hashtag#WorldSightDay, we recognize the importance of discussing eye health with your healthcare provider. Learn about Verily Numetric Retinal Service, our end-to-end retinal screening solution that enables greater access to precision retinal imaging.
